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Abstract 
 
Current treatment strategies for the treatment of brain tumor have been hindered primarily by the 
presence of highly lipophilic insurmountable blood-brain barrier (BBB). The purpose of current 
research was to investigate the efficiency of engineered biocompatible polymeric nanoparticles 
(NPs) as drug delivery vehicle to bypass the BBB and enhance biopharmaceutical attributes of 
anti-metabolite methotrexate (MTX) encapsulated NPs. The NPs were prepared by solvent 
diffusion method using cationic bovine serum albumin (CBA), and characterized for 
physicochemical parameters such as particle size, polydispersity index, and zeta-potential; while 
the surface modification was confirmed by FTIR, and NMR spectroscopy. Developed NPs 
exhibited zestful relocation of FITC tagged NPs across BBB in albino rats. Further, hemolytic 
studies confirmed them to be non-toxic and biocompatible as compared to free MTX. In vitro 
cytotoxicity assay of our engineered NPs on HNGC1 tumor cells proved superior uptake in 
tumor cells; and elicited potent cytotoxic effect as compared to plain NPs and free MTX 
solution. The outcomes of the study evidently indicate the prospective of CBA conjugated poly 
(D,L-lactide-co-glycolide) (PLGA) NPs loaded with MTX in brain cancer bomber with 
amplified capability to circumvent BBB. 
Keywords: Poly (D,L-lactide-co-glycolide); Nanoparticles; Methotrexate; Cationic bovine 
serum albumin; Brain targeting; Brain tumor.  
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1. Introduction  
Brain tumors constitute a solicitous and unsolved problem in the treatment because of 
inadequacy in bypassing the blood brain barrier (BBB)1,2 and mitigation of brain tumor is still 
the foremost challenging obligation3. BBB, a highly lipophilic barrier consist of the vascular 
structures composed of physical obstacle (tight junctions of astrocytes and endothelial cells), and 
well organised traffic controller of the metabolic barriers (multidrug resistance (MDR) 
pathways), that is managing the transport of bioactive materials across the BBB 4–7. The Cassette 
transport pump (p-glycoprotein) shows fundamental role in the drug efflux at the level of BBB 8. 
However, hydrophobic small molecular drugs can be easily transported across the BBB; and 
diverse attempts have been made to transport active molecules across the BBB 9,10. The 
successful management of brain tumor necessitates the bypassing, inactivate or suppress the 
metabolic BBB barriers 11. Therefore, expansion of an efficient system to bear the active 
molecules across the BBB has been a major challenge in research and stress must therefore be 
resolute on developing approach that enhances the bioavailability in the central nervous system 
(CNS). 
Nanotechnology indeed exploited in the most of the pharmacological complication of 
active molecules that results in increment in their therapeutic efficiency 12–15. Biocompatible 
nanostructured systems confess the interactions with biomolecules and interior environment of 
the cell and may sidestep the highly lipophilic physical obstacle that limits the passage of wide 
verity of therapeutic agent across BBB 16–18. Nowadays surface engineering of nanocarriers for 
target specific delivery of active molecules have been considered a viable strategy for the 
improved therapeutic efficacy in the management of brain tumor19–22. Thus, targeting strategies 
are capable of crossing barriers present in BBB to overcome the limited transport across it. Out 
of various approaches, adsorptive transcytosis via cationic bovine serum albumin (CBA) has 
been scrutinize to bypass BBB without influencing the integrity of tight junction at BBB 23–25. 
Surface modification of NPs finesses the BBB via adsorptive transcytosis where interaction 
between BSA and cell membrane) at the BBB demonstrate BSA preferentially encourage 
transport of nanocarriers across BBB 26–29. 
Methotrexate (MTX), a dihydrofolate reductase (DHFR) inhibitor acting in S-phase of 
the cell cycle plays a crucial role in the treatment of brain cancer by introducing itself within the 
folate stacks30,31. However, the inability to deliver MTX across BBB owing to its hydrophilic 
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nature and the distribution of the drug at noncancerous sites has severely compromised its 
clinical application. Therefore, nanostructured drug delivery vehicles, which are able to bypass 
BBB and cell membranes of brain tumor cells is an urgent and inevitable requirement for the 
treatment of brain tumors. United States Food and Drug Administration (US-FDA) approved the 
biodegradable non-immunogenic, biocompatible polyester polymers such as poly (D,L-lactide-
co-glycolide) (PLGA) in targeted drug delivery of drugs for various ailments32–35. 
The prepared NPs formulation engineered with CBA was physico-chemically 
characterized and evaluated using in vitro, ex vivo (cell line) and in vivo studies. Moreover, a 
comparative study of brain uptake of FITC tagged NPs following intravenous injection was 
confirmed by fluorescence microscopy. In nutshell, the present study with CBA modifiedPLGA-
NPs encapsulated MTX opens new horizon not only to understand the difficulties but also 
improvement in management of effective treatment of brain cancer. 
2. Materials, methods and Instrumentation 
2.1. Materials 
MTX, bovine serum albumin (BSA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
and (EDC) were purchased from Sigma Aldrich (Germany). PLGA, 50:50), N-hydroxy 
succinimide (NHS), Di-methyl-sulphoxide (DMSO), PluronicF-68(PF-68), FITC, Triton-X100 
were purchased from Himedia, Mumbai, India. Nylon membrane filter (0.22 µm) was purchased 
from Pall Gelman Sciences (USA). All other reagents and solvents were of analytical grade 
unless otherwise specified. Ultra-pure deionized water was used through the study. 
2.2. Preparation of cationic bovine serum albumin (CBA) 
CBA was prepared from BSA following the well-established procedure reported earlier 
with trivial modifications (Feng et al., 2009). Briefly, 0.5 g of BSA was treated with little 
exceeding of ethylenediamine (EDA) previously solubilised in conjugation buffer (MES; 0.2 
mol/L) at 4±1 °C while being agitate using magnetic stirrer (Remi, India) and the pH was 
adjusted to 4.7. Supplementary, 50 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) was added and allowed to keep undisturbed for 2 h in dark, at ambient temperature. The 
reaction was continued by addition of 0.4 ml of acetate buffer (2 mol/L; pH 4.75). Finally, the 
solution was dialyzed extensively against ultrapure deionised water for 48 h, lyophilized and 
stored in hermetically sealed container. Further, BSA and CBA were further characterized using 
NMR (Bruker DRX, USA) and FTIR spectroscopy (Perkin-Elmer, USA). 
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2.3. Fabrication of nanoparticles  
The MTX loaded PLGA NPs were prepared in accordance to the solvent-diffusion 
technique described by Song et al., 2006 36 with slight modifications. Briefly, MTX was 
dissolved in PBS (pH 7.4)/DMSO. Subsequently, aqueous solution of Pluronic® F-68 (PF-68) 
(PBS; pH 7.4) was added as a stabilizer to the drug solution. To it 1% w/v PLGA solution (the 
organic phase; 10 ml) in ethyl acetate was added drop-wise into 20 ml of an aqueous phase 
consisting drug and stabilizer under regular magnetic agitation (REMI Instrument India). This 
pre-emulsion was maintained above the melting temperature using a hot water bath and the 
stirring of high speed was set out to attain a pre-emulsion phase followed by sonication. In 
addition, a measured volume of ultra-pure deionized water was supplied to the o/w emulsion 
under gentle stirring to facilitate the diffusion of organic phase into an aqueous solvent leading to 
the formation of MTX loaded PLGA NPs (MTX-NPs). Subsequently, NPs dispersion was 
filtered through 0.22 µm membrane filters. Finally, the MTX-NPs dispersion was lyophilized 
(Heto Drywinner, Denmark, Germany) and stored for further studies. FITC labeled NPs were 
prepared by co-encapsulation of FITC along with MTX in PLGA NPs. 
2.4. Fabrication of CBA conjugated MTX loaded PLGA NPs (CBA-MTX-NPs) 
Freeze dried MTX-NPs were dispersed in ultra-pure deionized water at a concentration of 
20 mg/ml. Subsequently, 50 mg N-hydroxy succinimide (NHS) was added and allowed to be 
agitated for next 6 h followed by addition of EDC (15 mg) while constant stirring (Magnetic 
stirrer; Remi, India) for 48 h at ambient temperature. Afterwards, CBA (50 mM) was added 
while agitating all night (2000 rpm) to facilitate its conjugation with the MTX-NPs. The 
dispersion was then finally dialyzed against ultra-pure deionized water for 30 min to take away 
free CBA and other impurities followed by lyophilization (Heto Drywinner, Denmark, 
Germany). 
2.5. Characterization of nanoparticles  
2.5.1. Measurement of particle size and zeta potential  
The average particle size and poly dispersity index (PDI) of MTX-NPs and CBA-MTX-
NPs was determined by a Zetasizer (DTS ver. 4.10, Malvern Instruments, England). Briefly, 
nano-particulate sample dispersion was added in polystyrene cuvettes diluted with ultra-pure 
deionized water and analyzed at a 90° fixed angle. The zeta potential of NPs formulation was 
measured by determining electrophoretic mobility with a laser-based multiple angle particle 
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electrophoresis analyzer, Malvern Zetasizer (DTS Ver. 4.10, Malvern Instruments, England). 
The nanoparticles were suspended in ultra-pure de-ionized water and kept in an electrophoretic 
cell with an electric field of 15.24 V/cm and the zeta potential was measured.  
2.5.2. Scanning electron microscopy 
Surface morphology was determined by scanning electron microscope (SEM). In brief, 
the NPs powder was sprinkled on a double adhesive tape which was stuck on an aluminium stub. 
Following this the stubs were coated with gold at a thickness of about 300 Å by using a sputter 
coater. All NPs and examined under a SEM (LEO 435 VP, Eindhoven Netherlands) at an 
acceleration voltage of 30 kV and photographs were taken at various magnifications. 
2.5.3. Encapsulation efficiency 
The drug encapsulation efficiency was estimated using a dialysis method for separating 
unloaded MTX from the NPs. This was then analyzed spectrophotometrically to indirectly 
determine the amount of drug bound with the NPs. Momentarily, 5 ml of the MTX-NPs 
dispersion was placed into a dialysis bag (MWCO 1000 KDa, Himedia, India) and dialyzed 
against 50 ml of 0.1N NaOH for 60 minutes with magnetic stirring (50 rpm). Samples (0.5 ml) 
were withdrawn occasionally and collected into HPLC vials (Himedia, India) until no drug was 
detected in the receptor compartment37. All samples (injection volume – 10µl) were quantified 
for MTX content by HPLC at a flow rate of 1ml/min at 302 nm and at 40°C. Samples were 
loaded into the HPLC system to quantify the unentrapped amount of MTX, so as to quantify 
indirectly the amount of entrapped MTX within theNPs38–40. The same exercise was carried out 
to measure the entrapped drug in CBA conjugated NPs and the quantification was performed 
using HPLC (Shimadzu, Japan). The reversed phase C18 column (4.6 mm×250 mm, 5µm) was 
used for chromatographic separation. The mobile phase was a mixture of buffer (pH 6.0) and 
acetonitrile at a ratio of 9:1. The buffer consisted of 0.12 M di-sodium hydrogen orthophosphate 
and 0.03 M citric acid. 41. 
2.6. In vitro release study 
The ability of NPs to release drugs into external media was determined by conducting the 
in vitro drug release assay on the developed NPs. The dialysis tube diffusion technique was used 
to estimate in vitro release of MTX from MTX-NPs and CBA-MTX-NPs. The fixed volume of 
the prepared nano-particulate formulations (5 ml) were poured into the dialysis tubing (MWCO 
1000 KDa), tied at both ends and immersed into receptor media consisting 100 ml of phosphate 
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buffer saline pre-equilibrated at 37±2°C followed by moderate stirring (magnetic stirring;100 
rpm). 0.5 ml sample from recipient compartment was withdrawn intermittently and an equal 
quantity of fresh medium was added after each sample withdrawal in a receptor compartment to 
maintain a constant sink volume over the experiment. The same practice was adopted for the 
determination of drug release profile at pH 5.4 (mimicking acidic tumor environment). Samples 
were analyzed by HPLC using same method described above and the amount of MTX released 
over time was quantified41,42.  
2.7. Ex vivo study 
2.7.1. Cytotoxicity Study 
Human brain cancer cell lines (C6 glioma) was purchased from the National Center for 
Cell Sciences (NCCS), Pune, India; and cultured in DMEM (Dulbecco’s Modified Eagle’s 
Medium; Himedia, India) supplemented with 10%v/v heat-inactivated fetal bovine serum (FBS), 
1%v/v streptomycin, 3 mM glutamine in a 37±2°C humidified incubator and 5% CO2 
atmosphere. Cytotoxicity of NPs was evaluated by sulforhodamine B (SRB) staining assay 43. 
This assay is based on measurement of optical density for the determination of cell survival and 
proliferation. Principally this assay determines the metabolic activity of viable cells. 
Exponentially growing C6 glioma cells were plated at a density of 7×104 cells/ml in 24 well 
plates (Sigma, Germany). The cells were then incubated with predetermined concentrations 
(100.0–0.01 µM) of MTX (free MTX; MTX-NPs, CBA-MTX–NPs and CBA [1 mg/ml]+ CBA-
MTX–NPs) under restricted environment for 72 h. Afterwards, 20µl of cold trichloroacetic acid 
(TCA; 50%) was added to each well and kept undisturbed for an hat 4°Cto facilitate cell fixation. 
Subsequently, the plates were rinsed with ultra-pure deionized water, dried and stained with 50-
60 µl of 5%w/v SRB reagent (constructed in 1%v/v acetic acid) for an h. Then, 150 µl of acetic 
acid was aspirated to remove the excess of SRB reagent. In each well, TRIS was added and well-
mixed on a shaker for few minutes. The optical density (OD) of each well was then measured at 
490 nm via microplate spectrophotometer (Model 680, Bio-Rad, Japan).  
2.7.2. Cellular uptake assay  
Cellular uptake efficiency of NPs was evaluated as a function of ligand using 
fluorescence activated cell sorters (FACS) instrument (BD Biosciences FACS Aria, Germany) 
againstC6 glioma cells. Glioma cells were cultured in accordance with the process described 
under cytotoxicity studies. Briefly, cells were seeded in 6 well plates (Sigma, Germany) at a 
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2×106 cells/ml using fresh culture medium and allowed to suspend for 12 h in humidified 
incubator at 37±2°C with 5% CO2 atmosphere. Cellular internalization of different dose of MTX 
formulation was determined by in vitro incubation of cells with fluorescein isothiocyanate 
(FITC), FITC labeled NPs and CBA [1mg/ml]+ CBA conjugated FITC labeled NPs in separate 
wells for 1 h. NPs which were adhered to the cell surface were detached by washing each well 
twice with PBS (pH ~7.4). Further, cells were trypsinized (0.1% w/v), kept for 5 min, and 
harvested by adding 1 ml PBS (pH ~7.4) followed by probe sonication for five times to obtain 
the cell lysate. Finally, cell lysate was centrifuged at 12,000 rpm for 10 min, and the supernatant 
was subjected to florescence assay using FACS. Same procedure was followed to study the 
cellular uptake profile after 2 and 6 h 3,44.  
2.8. In vivo pharmacokinetic and biodistribution studies 
The in vivo validation of the developed formulation (MTX-NPs and CBA-MTX-NPs) 
was performed to evaluate the CBA mediated transport while bypassing the BBB, and drug 
distribution in various organs of Balb/c mice (20–25 g; either sex). All animal experimentation 
procedures were carried out with prior permission and approval by Institutional Animals Ethical 
Committee, Dr. Hari Singh Gour University, Sagar (M.P.; India). The animals were fasted all the 
night with free access to water ad libitum. A short incision was made through the skin to expose 
the cranium and approximately 6×105 C6 glioma cells/10 µl in serum-free 2%v/v DMEM were 
stereotaxically rooted into the right forebrain of each animal45. 
Previously weighed tumor bearing animals were randomly divided into four groups of 
nine animals each. MTX, MTX-NPs and CBA-MTX-NPs were dispersed in normal saline. The 
formulations were administered at a dose of 5.0 mg/kg body weight through the lateral tail vein 
of animals of first, second and third groups, respectively46. Animals of fourth group served as a 
control for this study. Approximately 300 µl blood samples were withdrawn from retro-orbital 
plexus under mild anesthesia at 0.16, 0.5, 1.0, 2.0, 3.0, 5, 8, 12, 18, 21 and 24 h intervals in 
heparinized tubes. Blood samples were collected from three animals of each group and were 
assassinated by cervical dislocation after the study. 
The organs viz. brain, liver, kidney, heart spleen and tumor were isolated carefully, 
weighed and stored at −80 °C until experimentation. Afterwards, blood sample was collected 
from other three animals (n = 6) of each group for 2–8 h intervals, euthanized and different 
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organs were isolated. This exercise was also repeated for last three animals of each group for 8–
24 h intervals. 
Plasma was separated from blood samples by centrifugation at 10,000 rpm for 15 min. 
Afterwards, 100 µl of plasma was filtered into micro-centrifuge tube and same quantity of 
acetonitrile was added to precipitate the protein. 
At the same time, the organs were chopped and homogenized to detach the tissues, 
vortexed for one minute, and kept undisturbed for 30 min. Tissue homogenates were then treated 
with100 µl of acetonitrile. Further, the serum and tissue homogenates earlier admixed with 
acetonitrile were vortexed for 1 min, and subsequently centrifuged at 5000 rpm for 15 min. The 
supernatant was filtered through a 0.22 µm syringe filter, collected in HPLC vials (Himedia, 
India), and quantified for MTX content. Quantification of MTX was done in serum as well as in 
various tissues viz. brain (glioma cells), heart, liver, spleen and kidney was performed by HPLC 
method as described earlier 41,47. 
2.9. Hemolytic toxicity 
Hemolytic study was performed following the procedure described earlier with slight 
modifications 39,48. Briefly, whole human blood samples were collected from a healthy person 
(with kind consent) and heparinized in HiAnticlot blood collection vials (Himedia, India). 
Subsequently, the red blood cells (RBCs) suspension was centrifuged and resuspended in normal 
saline. Two mL of the RBCs suspension was separately dispersed in normal saline solution 
producing no hemolysis (served as control ‘0 % hemolysis’) and in distilled water considered to 
be producing 100% hemolysis. One ml of adequately diluted plain MTX solution, MTX-NPs, 
and CBA–MTX–NPs were incubated individually with 2 ml RBCs suspension and the volume 
was made up to 10 ml with normal saline.  
The formulations were taken in such amount that the resultant final concentration of 
MTX was equivalent in every case so as to facilitate the assessment of extent of hemolysis 
followed by effect of tween 80 (Himedia, Mumbai, India) coating on hemolysis. Further, the 
formulations were allowed to incubate at 37±1 °C for 30 min, followed by centrifugation at 4000 
rpm for 10 min. Subsequently, supernatants were taken and diluted with an equal volume of 
normal saline and absorbance was measured by UV-Visible spectrophotometer (Schimadzu, 
1601 Japan) at 540 nm against normal saline diluted similarly as blank. The percent hemolysis 
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was then determined for each sample by taking absorbance of distilled water which was assumed 
to be producing 100% hemolysis.  
2.10. Data analysis 
Statistical analysis of the data was articulated as the mean ± S.D and statistical analysis 
was computed using one-way analysis of variance (ANOVA) with a Tukey–Kramer multiple 
comparison Post- test using GraphPad InStat™ software (GraphPad Software Inc., San Diego, 
California). A probability level of p<0.05 was considered to be significant. 
3. Results and discussion 
3.1. Preparation of CBA  
The FTIR spectroscopy of pure BSA (Fig. 1A) shows the distinctive peaks at 3280.16 
cm−1 (stretching vibration of –OH), 2966.17 cm−1 amide (–N-H stretching vibration), 1635.01 
cm−1(C=O stretching vibrations), 1515.49 cm−1 (coupling of bending vibrate of N–H and 
stretching vibrate of C–N) cm−1, 1388.88 cm−1 (aromatic -C=C-) and 1037.46 cm−1 (C–O 
bending) (Fig. 1A). After cationization discrepancy in the FTIR peaks are understandable with 
elevated intensity at parallel wavelength because of the presence of auxiliary ethylene amine 
group in CBA incorporated during cationization. Shifting of FTIR peak of –OH groups, C=O 
stretching, and disappearance of 1388.88 cm−1 (aromatic -C=C-stretching) confirmed the 
cationization of BSA (Fig. 1B). In NMR spectroscopy, amine group (-NH2) shows high shielding 
effect and the obtained spectra of CBA illustrated its characteristic peak at 3.5 ppm which 
confirms the presence of amine group in CBA (Fig. 2A). 
3.2. Preparation of CBA conjugated MTX loaded NPs (CBA-MTX-NPs) 
The NPs were fabricated by an emulsification-diffusion method and the carboxylic group 
of NPs was conjugated to amine functionalities of CBA according to a previously reported 
method as reported earlier with slight modifications 49–51. This technique involved the quick 
diffusion of solvent across the solvent–lipid phase into aqueous phase followed by evaporation 
of solvent leading to enhanced rigidity of the NPs.  
Addition of CBA in presence of NHS and EDAC leads to formation of amide (–CONH–) 
bond between amine (–NH2) groups of CBA and carboxylic acid (–COOH) present on the 
surface of NPs. Amalgamation of CBA appended NPs was further confirmed by FTIR and NMR 
spectroscopy. The presence of peaks depicting N–H stretch at 3432.01cm−1, C=O stretching at 
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1723.95 cm−1 and C–O stretching at 1360.42 cm−1 confirmed the amide bond formation, and 
hence the conjugation between NPs and CBA (Fig. 1C). In NMR Spectra, acidic group (-COOH) 
demonstrate its peak at deshielded position or away from the reference line of tetra methyl silane 
in NMR spectra. In NMR spectra of CBA-MTX-NPs, distinguish peak with less intensity at 8.5 
ppm indicated that the most of the free carboxylic group get saturated with amine group of CBA, 
thus confirmed the formation of amide bond between carboxylic groups of MTX-NPs made up 
of PLGA and amine groups of CBA (Fig. 2 B). 
 
3.3. Characterization of nanoparticles 
3.3.1. Size, Zeta Potential and Surface morphology 
The average particle size of CBA conjugated MTX-NPs as measured by dynamic light 
scattering technique was found to be larger than that of unconjugated formulation (Fig. 3 and 
Table 1). The disparity in the average size may be due to the conjugation of CBA on the surface 
of MTX-NPs. The average particle size of MTX-NPs was found to be108.3±3.1nm while in case 
of CBA conjugated formulation it was 120.9±4.4 nm. The mean diameters of NPs were well 
below 200 nm and these fallouts are in harmony with SEM photographs of the CBA conjugated 
NPs (Fig. 4A and B). 
Zeta potential is an imperative criterion in order to establish the storage stability of 
nanometric particulate system. The zeta potential of MTX-NPs and CBA-MTX-NPs 
formulations was found to be -13.7± 0.4 mV and -5.55± 0.3 mV, respectively (Fig. 3 and Table 
1). The higher negative magnitude of zeta potential might be ascribed to the –COO (carboxylic) 
group exist at the surface of polymeric NPs. The lowering of zeta potential value upon CBA 
conjugation was reasoned to be due to subsequent replacement of –COO group with terminal 
amine (NH2) groups after protein conjugation
51. The elevated magnitude of zeta potential offers 
repulsive inter-particle interaction preventing aggregation of the nanoparticles52. 
3.3.2. Entrapment Efficiency 
MTX-NPs showed appreciably higher entrapment efficiency (79.9±2.4%) as compared to 
the CBA conjugated NPs (71.3±1.8%) (Table 1). Dissolution and subsequent loss of surface 
adhered MTX from MTX-NPs upon addition of NPs in the medium may be ascribed to the 
divergence in entrapment efficiency. These outcomes are consistent to the results obtained in 
earlier investigations53. 
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3.4. In vitro drug release profile 
In vitro drug release in pH 7.4 and 5.4 on plain and conjugated NPs demonstrated a 
biphasic drug release pattern suggesting an early burst, followed by a lag phase and a later 
apparent-zero order phase (Fig. 4C). MTX release of 20.26±1.58% and 28.9 ±2.45% was 
attained from CBA-MTX-NPs and MTX-NPs correspondingly in the PBS (pH 7.4). On the other 
hand, 21.4±1.03% and 33.9 ±1.15% of MTX was found to be released from CBA-MTX-NPs and 
MTX-NPs, respectively in the acidic media (pH 5.4) until the end of 8thh (Fig. 4C). The most 
probable reason that may be accounted to this rapid release of MTX can be accounted to the 
release of drug adsorbed on the surface of NPs. Furthermore, at pH 7.4, the cumulative MTX 
release from CBA-MTX-NPs and MTX-NPs was 73.51±3.64% and 88.3±4.85%, respectively at 
the end of 144 h. In other case, 95.60±3.53of MTX was found to be released from CBA-MTX-
NPs at the end of 144 h. The extended release could be ascribed to the diffusion of drug 
molecules across the polymeric milieu of the NPs. However, a sizeable decrease in cumulative 
release of MTX from their CBA conjugated formulations was observed in comparison to their 
unconjugated counterparts at both pH values (pH 7.4 and pH 5.4). This may be ascribed to the 
structural integrity conferred by CBA, therefore providing a diffuse double layer obstacle and 
offering a steric hindrance to diffusion of drug9,54.Furthermore, accelerated degradation of PLGA 
and lessening of ionic interaction between drug and PLGA at an acidic pH might be accountable 
for faster drug release at lower pH. Acidic pH catalyzes the cleavage of ester linkages in the 
polymer backbone and augments the erosion of polymeric matrix 55. As a result, PLGA NPs 
could be anticipated to afford a pH-stimulating release of entrapped MTX at acidic milieu of 
tumor and might facilitate ligand mediated transcytosis as well.  
3.5. Ex vivo studies 
3.5.1. Cytotoxicity and cell uptake studies  
The cytotoxic response in term of % growth inhibition of free MTX, MTX-NPs and 
CBA-MTX-NPs was evaluated by SRB assay against C-6 glioma cells. Percent Cellular 
inhibition response against all formulation was found to be concentration dependent. None of the 
formulation showed any effect on the survival of cells when the MTX equivalent concentration 
was below 1 µM, and in all these cases the cell viabilities were found to be well above 90% 
survival rate (Fig. 5 A, B & C).  
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Experiments conducted on xenografts model undoubtedly exemplify a dose dependent 
cytotoxic response that is a decrease in % cell survival with increase in concentration of drug. 
Nearly100 % of the cells were killed when concentration of MTX was 100 µM in case of all the 
formulation. Probably, the cytotoxic action of drug depends upon adequate access of drug in the 
cell and not merely by its presence in the adjacent milieu of a cell over the incubation period (72 
h). In concentration range (1–100 µM) of MTX, the cytotoxic effect was sort out as CBA-MTX-
NPs > MTX-NPs > CBA+ CBA–MTX-NPs > MTX (Fig. 5 A, B & C). 
Maximum intracellular entry of CBA-MTX-NPs was conferred upon CBA conjugation via 
adsorption mediated endocytosis. Consequently, extended release of MTX leads to considerable 
higher cytotoxic action as compared to free MTX or MTX-NPs. The cytotoxic effects via MTX-
NPs were measured less than CBA appended NPs possibly due to their entry in absence of any 
active transport mechanism and is mediated merely by passive diffusion mechanism. 
Furthermore, the nano metric size of the NPs may lead to the enhanced permeation and retention 
(EPR) effect and coating of CBA enhanced the adsorption as well as cell permeability due to 
changes in cell membrane fluidity. Besides, the %cellular inhibition was found significantly less 
when cells were incubated with CBA-MTX-NPs + CBA (1 mg/ml). This may be credited to the 
competitive inhibition of CBA functionalized NPs with free CBA. Free CBA was preferentially 
up taken by the cells, and therefore little entry of CBA-MTX-NPs was observed. The results are 
lined up with previous outcomes reported by Storm et al., 200256. 
3.5.2. Cellular Uptake Study 
Imperatively CBA-MTX-NPs facilitates higher cytotoxic response in C-6 cells, in vivo 
the ligand anchored formulation would promptly experience transcytosis therefore evading the 
possibility of marked increase in % cellular uptake effect on C-6 cells as compared to 
unconjugated formulation and fluorescence marker alone. 
The efficacy of cellular uptake as a function of CBA conjugation and incubation time was 
determined using flow cytometry. Two h post incubation of plain FITC, FITC labeled MTX-
NPs, FITC labeled CBA-MTX-NPs, and free CBA + FITC labeled CBA-MTX-NPs, the percent 
fluorescencein C-6 glioma cells was found to be 9.8 ± 2.4%, 14.1 ± 3.1%, 33.6 ± 3.3%, and 11.7 
± 3.2%, respectively (Fig. 5 D). Fluorescence intensity augmented with time (p≤0.05), which 
was merely 32.7±2.6%, 51.5±3.2%, 78.6±3.8%, and 39.6±3.3%, respectively after 6 h. The 
higher uptake of CBA conjugated formulation was possibly due to CBA residues tethered on the 
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facade of NPs when compared to unconjugated NPs (p < 0.05). This foremost cellular 
localization maybe credited to the adsorption mediated endocytosis mechanism facilitated by 
CBA. Furthermore, FITC alone and FITC labeled MTX-NPs illustrated fluorescence due to 
diffusion/endocytosis/phagocytosis mediated non-specific adsorption onto cell surfaces. In 
contrast incubation of free CBA along with FITC labeled CBA-MTX-NPs led to distinctly 
restrict entry into the tumor cell lines. This may be ascribed to competitive inhibition of CBA 
tethered NPs with free CBA. Free CBA preferentially gained access into the cells, and thus little 
entry of FITC labeled CBA-MTX-NPs was evaluated. The outcomes are lined up with previous 
studies 56. 
3.6. In vivo pharmacokinetic and biodistribution studies 
Biodistribution studies were carried out to examine the efficacy of CBA conjugated NPs 
in the delivery of anticancer agents to target tumor tissues while circumventing the BBB and also 
bypass peripheral tissues (kidney, heart, liver, etc.). Following injection of MTX entrapped in 
NPs, the initial maximum concentration attained was slightly lower than plain MTX (Fig. 6A). 
After 2 h of administration, the content of MTX when injected as plain solution in 
kidney, liver, heart, spleen, and tumor tissues was 31.81 ± 1.41 µg/g, 10.13 ±0.97 µg/g, 5.3±0.7 
µg/g, 8.1±0.87 µg/g, and 2.9±0.4 µg/g, respectively (Fig. 6A). The information evidently 
advocates the utmost NPs uptake by liver/spleen (organs rich in cells of RES) and access to the 
kidney, which is primary organ for its clearance. A nominal concentration of MTX was 
estimated in brain, the BBB acts as a main obstacle for delivery and further significantly impedes 
therapeutic effectiveness. Furthermore, the concentration of MTX declined rapidly in all the 
organs being untraceable in kidney and brain following 24 h of administration. This designates 
rapid removal/elimination/metabolism of drug from the body when administered in its original 
form. 
On the contrary, after 24 h of formulation administration, the concentrations of MTX 
loaded in MTX-NPs were estimated to be: 11.51±1.09, 7.22±0.97, 3.31±0.91, 6.95±0.1.25 and 
51.7±3.4 µg/g in the liver, kidney, heart, spleen and tumor, respectively (Fig. 6A). In the case of 
CBA conjugated NPs formulations, 112.69±6.41 µg/g of MTX was found in tumor tissues, 
9.19±0.95 µg/g in the liver with a less amount in the heart and 5.1±0.57 µg/g in kidneys, and 
5.63±0.49 µg/g in the spleen after 24 h (Fig. 6A). Sufficient amount of MTX was detected in 
liver and spleen following administration of MTX as MTX-NPs, and may be ascribed to the 
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uptake of polymeric particles by mononuclear phagocytic system. A slight access of MTX 
concentration in brain tissues was also observed. An improved residence time of MTX in the 
systemic circulation was also noted upon incorporation of MTX inside NPs that facilitated the 
redistribution process of drug into various tissues. Despite, deficiency of a targeting entity in 
case of MTX-NPs leads to non-selective/ non-specific distribution and thus the effect was not 
prominent. 
The amount of MTX determined in kidney, liver, heart, spleen, and brain tissues was 
6.03±0.39 µg/g, 9.24±0.76 µg/g, 0.94±0.04 µg/g, 8.03±1.01 µg/g and 19.89 ± 1.16 µg/g, 
respectively following 2 h administration of CBA-MTX-NPs (Fig. 6A). Importantly, after 2 h the 
MTX concentration with CBA-MTX-NPs in brain was increased by 39.26 and 2.17 folds when 
compared to free MTX and MTX-NPs. The outcomes undoubtedly advocate the targeted 
delivery of MTX to brain with CBA decorated NPs. This may be ascribed to CBA tethering that 
make possible to NPs to pass across the BBB by adsorption mediated transcytosis 27,28. The 
stratagem may also facilitate enlarge the therapeutic efficacy by providing possibility to diminish 
the dose of bioactive moieties and drug incorporated delivery vehicles. 
Circulation life time, plasma profile as well as therapeutic effectiveness of MTX was enormously 
altered after entrapment of MTX inside nanoparticles and upon conjugation of CBA. Plasma 
profiles of various MTX formulations after single i.v. injection in Balb/c mice were 
demonstrated in Fig 6B. Concentration of MTX in serum after i.v. administration of free MTX 
was estimated to be 1.57±0.052 µg/ml, after 30 min and 0.13±0.039 µg/ml after 24 hrs. This 
steep decrease might be due to the rapid elimination of MTX from the kidneys and instantaneous 
distribution in various organs. Conversely, after administration of the MTX loaded nanoparticles 
formulation, the concentration of MTX in serum was significantly low. The maximum 
concentration of MTX estimated in the serum following 12 h was calculated to be 1.11±0.047 
and 1.19±0.087 µg/ml for MTX-NPs and CBA–MTX–NPs respectively. Though, 0.27±0.041 
and 0.68±0.71 µg/ml of MTX was measured in the plasma until the end of 24 and 20 h following 
administration of CBA-MTX-NPs and MTX-NPs, respectively (Fig. 6B). The outcomes merely 
signify the long circulation characteristic of NPs while ligand tethered formulation having the 
extended residence time. Concentration of MTX in serum was sustained to a greater extent in 
case of CBA-MTX-NPs than that of MTX-NPs probably due to the double barrier effect to drug 
diffusion upon surface modification with CBA54. The information offered to this point merely 
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imply CBA-MTX-NPs have noticeably enhanced bioavailability and apparently extended 
retention in systemic circulation and the result could not be accomplished via pre-treatment of 
mice with MTX-NPs or plain MTX. 
3.7. Hemolytic toxicity 
Concentration at 0.1 µM (equivalent of MTX), free MTX exhibited 17.9±0.6% 
hemolysis; however, MTX-NPs and CBA–MTX-NPs formulations displayed 11.7±0.3%, and 
6.1±0.51% hemolysis, respectively (Fig. 6C). The toxicity of polymeric NPs was not as much of 
in comparison to free MTX due to the incorporation of drug in a biocompatible nanostructured 
milieu. However, the hemolytic toxicity of NPs with functionalities at the surface is a major 
limitation in the use of such systems and was adequate to exclude its use as vehicles for drug 
delivery. CBA anchored to the NPs surface appreciably diminishes the hemolysis of the RBCs 
certainly due to inhibition of communication of RBCs with the anticancer moiety associated with 
the surface of MTX-NPs. 
4. Conclusions 
NPs are the biocompatible nano-carriers which have been expansively investigated for 
the delivery of therapeutics. This is the first report of its own kind that offers an insight to use of 
cationic bovine serum albumin tethered biodegradable polymeric nanostructured carriers for 
brain tumors exploiting adsorption mediated transcytosis to circumvent the highly lipophilic 
BBB. The present study discloses CBA functionalized polymeric nanoparticles as proficient 
vectors to carry large doses of anti-cancer drug for its sustained and targeted delivery. CBA 
tethered NPs incorporating MTX demonstrated cytotoxicity higher than that of plain MTX on C-
6 glioma cells at all the concentration tested. The formulation proficiently navigated huge doses 
of anti-cancer therapeutic agent across the BBB. The best promising therapeutic response and 
diminution in annoying side effects may be facilitated by site specific delivery strategy. 
Nevertheless, meticulous exercises require to be carried out to attain any unambiguous 
generalization. 
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Table captions: 
Table 1: Zeta Potential, Particle Size, PDI and %Drug Entrapment of nano-formulations. 
 
 
 
 
Figure captions: 
 
Fig.1: FT-IR spectra of (A) BSA, (B) CBA and (C) CBA-MTX-NPs.  
Fig. 2: NMR of (A) CBA and (B) CBA-MTX-NPs. 
Fig.3: Particle size of (A) MTX-NPs and (B) CBA-MTX-NPs. Zeta potential of (A) MTX-NPs 
and (B) CBA-MTX-NPs. 
Fig.4: (A and B) SEM image of CBA-MTX-NPs and (C) In vitro release profile of MTX from 
MTX-NPs and CBA-MTX-NPs in PBS (pH 7.4) and PBS (pH 5.4). Inset graph represents the 
drug release at the initial time points. Each data point represents mean ± SD (n = 6). 
Fig.5: Cell cytotoxicity of Plain MTX, MTX-NPs, CBA-MTX-NPs and CBA+CBA-MTX-NPs 
(A) after 24 h, (B) after 48 h and (C) after 72 h. (D) Cellular uptake efficiency of plain FITC, 
FITC labeled MTX-NPs, FITC labeled CBA-MTX-NPs and CBA+ FITC labeled CBA-MTX-
NPs in C-6 glioma cells. Each data point represented as mean ± SD (n = 4). 
Fig.6: (A) Biodistribution of Plain drug and formulations attained at various time intervals in 
different tissues (n=6; p≤0.05*, a). *Significant difference between free MTX Vs MTX-NPs and 
CBA-MTX-NPs, a significant difference between MTX-NPs and CBA-MTX-NPs. (B) Serum 
concentration of MTX attained at various intervals (n=6; p≤0.05*,a). *Significant difference 
between free MTX Vs MTX-NPs and CBA-MTX-NPs, a significant difference between MTX-
NPs and CBA-MTX-NPs. (C) Comparative hemolytic toxicity study (n=6; p≤0.05*, a). 
*Significant difference between free MTX Vs MTX-NPs and CBA-MTX-NPs, a significant 
difference between MTX-NPs and CBA-MTX-NPs.  
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Table 1: Zeta Potential, Particle Size, PDI and %Drug Entrapment of nano-formulations. 
Formulation Code Zeta Potential 
(mV) 
Particle Size 
(nm) 
PDI %Drug 
Entrapment 
MTX-NPs -13.7± 0.4 108.3±3.1 0.015±0.004 79.9±2.4% 
CBA- MTX-NPs -5.55± 0.3  120.9±4.4 0.155±0.007 71.3±1.8% 
Results are presented as Mean ± SD (n=3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 21 of 27 RSC Advances
R
S
C
A
dv
an
ce
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
31
 A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
by
 Q
ue
en
's L
ibr
ary
 on
 09
/09
/20
16
 09
:24
:32
. 
View Article Online
DOI: 10.1039/C6RA17290C
22 
 
 
Fig.1: FT-IR spectra of (A) BSA, (B) CBA and (C) CBA-MTX-NPs. 
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Fig.2: NMR of (A) CBA and (B) CBA-MTX-NPs. 
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Fig.3: Particle size of (A) MTX-NPs and (B) CBA-MTX-NPs. Zeta potential of (A) MTX-NPs 
and (B) CBA-MTX-NPs. 
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Fig.4: (A and B) SEM image of CBA-MTX-NPs and (C) In vitro release profile of MTX from 
MTX-NPs and CBA-MTX-NPs in PBS (pH 7.4) and PBS (pH 5.4). Inset graph represents the 
drug release at the initial time points. Each data point represents mean ± SD (n = 6). 
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Fig.5: Cell cytotoxicity of Plain MTX, MTX-NPs, CBA-MTX-NPs and CBA+CBA-MTX-NPs 
(A) after 24 h, (B) after 48 h and (C) after 72 h. (D) Cellular uptake efficiency of plain FITC, 
FITC labeled MTX-NPs, FITC labeled CBA-MTX-NPs and CBA+ FITC labeled CBA-MTX-
NPs in C-6 glioma cells. Each data point represented as mean ± SD (n = 4). 
 
 
 
 
 
Page 26 of 27RSC Advances
R
S
C
A
dv
an
ce
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
31
 A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
by
 Q
ue
en
's L
ibr
ary
 on
 09
/09
/20
16
 09
:24
:32
. 
View Article Online
DOI: 10.1039/C6RA17290C
27 
 
 
Fig.6: (A) Biodistribution of Plain drug and formulations attained at various time intervals in 
different tissues (n=6; p≤0.05*, a). *Significant difference between free MTX Vs MTX-NPs and 
CBA-MTX-NPs, asignificant difference between MTX-NPs and CBA-MTX-NPs. (B) Serum 
concentration of MTX attained at various intervals (n=6; p≤0.05*,a). *Significant difference 
between free MTX Vs MTX-NPs and CBA-MTX-NPs, a significant difference between MTX-
NPs and CBA-MTX-NPs. (C) Comparative hemolytic toxicity study (n=6; p≤0.05*, a). 
*Significant difference between free MTX Vs MTX-NPs and CBA-MTX-NPs, asignificant 
difference between MTX-NPs and CBA-MTX-NPs.  
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